Kymera gains FDA Fast Track for KT-621 as Gilead licenses KT-200
Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.
Type 2 Inflammatory Disease
DiseaseRelated News
Sanofi Gains FDA Approval for Dupixent AFRS Indication and EU Opinion for Sleeping Sickness Drug
Sanofi receives FDA approval for Dupixent to treat allergic fungal rhinosinusitis and gains European endorsement for Acoziborole Winthrop as a sleeping sickness treatment, which will be donated to WHO.